Bondbloxx Bloomberg Ten Year Target Duration US Treasury ETF XTEN
43.86 USD +0.27 (+0.61%)
Nov 4, 2026, 2:50 PM EST
43.57 Day range 43.88
41.84 52-week range 47.49
- YTD
- -5.11%
- 1 year
- -6.22%
- Market cap
- 1.04B
- YTD return
- -5.11%
- 1-year return
- -6.22%
- Volume
- 234.59K
- Avg volume
- 325.35K
- Open
- 43.71
- Previous close
- 43.60
- Day's range
- 43.57 – 43.88
- 52-week range
- 41.84 – 47.49
3M -0.69 (-1.55%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 43.36
- 200-day average
- 45.01
Next earnings
Consensus EPS estimate 0.00.
About Bondbloxx Bloomberg Ten Year Target Duration US Treasury ETF
Under normal circumstances, the fund will invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in a portfolio of U.S. Treasury securities that collectively have an average duration of approximately 10 years, either directly or indirectly (e.g., through derivatives). The index is comprised of certain U.S. Treasury notes and bonds that are included in the Bloomberg U.S. Treasury Index. It is non-diversified.
News
BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Stake Reduced by DUTCH ASSET Corp 
BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) Stock Short Interest Report for September 
15,395 Shares in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Bought by Sax Wealth Advisors LLC 
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors 
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer 
Why Investors Are Eyeing Short & Long U.S. Treasury ETFs 
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer 
Park Avenue Securities LLC Sells 37,510 Shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN 
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer 
Heck Capital Advisors LLC Has $9.10 Million Stock Holdings in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN
Your note
Sign in to keep a note on XTEN — it syncs with the Stock Master app.